Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the efficacy of AZD9668 compared with placebo in
symptomatic COPD patients by assessing the effects on lung function and symptoms of COPD
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Formoterol Fumarate